| Market Capitalization (Millions $) |
3,672 |
| Shares
Outstanding (Millions) |
125 |
| Employees |
601 |
| Revenues (TTM) (Millions $) |
236 |
| Net Income (TTM) (Millions $) |
-369 |
| Cash Flow (TTM) (Millions $) |
9 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Arcus Biosciences Inc (NASDAQ:RCUS) is a biotechnology company that focuses on discovering and developing innovative immunotherapies to treat cancer. The company is headquartered in Hayward, California and was founded in 2015 by a team of experienced biotech executives.
Arcus Biosciences' main objective is to develop new and innovative cancer treatments that will revolutionize the way we treat this disease. The company's highly skilled team of scientists is working diligently to develop and commercialize cancer immunotherapies based on the latest advances in immunology and genomic analysis.
The company's pipeline is focused on small molecule therapies and antibodies that target key immunomodulatory pathways, with the goal of enhancing the immune system's natural ability to identify and destroy cancer cells. This approach is designed to treat a wide range of cancers, including solid tumors and hematological malignancies.
Currently, Arcus Biosciences has three clinical-stage product candidates in development, each with the potential to address a significant unmet medical need in the oncology space. The company's lead product candidate, AB928, is a small molecule dual adenosine receptor antagonist that is being evaluated in combination with chemotherapy, radiation, and other checkpoint inhibitors. The goal of this combination therapy is to enhance the anti-tumor immune response, improve the efficacy of existing cancer treatments, and improve overall patient outcomes.
Another key product in the company's pipeline is AB154, an anti-TIGIT monoclonal antibody that is being developed as a next-generation checkpoint inhibitor. This therapy is designed to block the TIGIT pathway, which plays a critical role in suppressing the immune system's natural response to cancer. The company believes that AB154 has the potential to be a highly effective therapy in combination with other cancer treatments.
The third product candidate, AB680, is a small molecule inhibitor of CD73, an enzyme that is involved in the adenosine pathway. This therapy is being evaluated in combination with other checkpoint inhibitors with the goal of enhancing the immune response against tumors and improving overall patient outcomes.
As a relatively young company, Arcus Biosciences has already made significant progress in the development of new and innovative cancer therapies. In addition to its strong product pipeline, the company has established partnerships with several other leading biotech and pharmaceutical companies, including Gilead Sciences, Roche, and Taiho Pharmaceutical. These partnerships provide the company with substantial resources and support to continue advancing its research and development efforts.
Overall, Arcus Biosciences is a highly innovative and dynamic biotechnology company that is focused on developing new and effective cancer therapies. With a strong pipeline of product candidates and a talented team of scientists and researchers, the company is well-positioned to make a profound impact in the field of oncology and improve the lives of patients affected by this devastating disease.
Company Address: 3928 Point Eden Way Hayward 94545 CA
Company Phone Number: 694-6200 Stock Exchange / Ticker: NYSE RCUS
|
1.75% 
70.59 %